Eliem Therapeutics, Inc. (ELYM) |
|
2.85 -0.04 (-1.38%)
|
08-18 07:02 |
|
Open: |
2.81 |
Pre. Close: |
2.89 |
|
High:
|
3 |
Low:
|
2.7601 |
|
Volume:
|
18,340 |
Market Cap:
|
76(M) |
|
|
|
|
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3 - 3.02 |
3.02 - 3.03 |
|
Low:
|
2.72 - 2.74 |
2.74 - 2.75 |
|
Close:
|
2.82 - 2.85 |
2.85 - 2.87 |
|
Technical analysis |
as of: 2022-08-17 4:22:58 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.18 One year: 4.89 |
| Support: |
Support1: 2.59 Support2: 2.16 |
| Resistance: |
Resistance1: 3.58 Resistance2: 4.19 |
| Pivot: |
2.94  |
| Moving Average: |
MA(5): 2.9 MA(20): 3
MA(100): 4.28 MA(250): 10.04 |
| MACD: |
MACD(12,26): -0.2  Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 31.6 %D(3): 32.2 |
| RSI: |
RSI(14): 39.2 |
| 52-week: |
High: 29.69 Low: 2.51 |
| Average Vol(K): |
3-Month: 67 (K) 10-Days: 33 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELYM ] has closed above bottom band by 27.1%. Bollinger Bands are 81.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 17 Aug 2022
Eliem Therapeutics (NASDAQ:ELYM) Price Target Lowered to $4.00 at SVB Leerink - Defense World
Tue, 02 Aug 2022
Wall Street Falters Pre-Bell as Pelosi's Expected Taiwan Visit Fuels Geopolitical Uncertainty - InvestorsObserver
Tue, 02 Aug 2022
Sector Update: Health Care Stocks Weaken in Choppy Session - InvestorsObserver
Tue, 02 Aug 2022
Eliem Therapeutics Shares Fall After Lead Program Scuttled >ELYM - MarketWatch
Mon, 18 Jul 2022
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder - Marketscreener.com
Mon, 16 May 2022
Eliem Therapeutics Reports First Quarter Financial and Business Highlights - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
27 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
33.1 (%) |
|
% Held by Institutions
|
74.7 (%) |
|
Shares Short
|
382 (K) |
|
Shares Short P.Month
|
756 (K) |
Stock Financials |
|
EPS
|
-2.54 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.84 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-24.3 |
|
Return on Equity (ttm)
|
-41.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-40 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-1.13 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.48 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
